|
SEARCH | SUBSCRIBE | ||
|
Medicare
Plan Covering Drugs Backed by AARP WASHINGTON, Nov. 17 — AARP, the largest and most influential
organization of older Americans, threw its weight behind a bill on Monday
that offers drug benefits to the elderly as part of the biggest
transformation of Medicare in its 38-year history. President Bush and Republican leaders in Congress stepped up their
efforts to win votes for the legislation, which would give private health
insurance companies a huge new role in Medicare. AARP's endorsement, long
coveted by Republicans in Congress, was considered a critical step in the
drive for passage of the legislation this year. The endorsement provides a seal of approval from an organization with
35 million members. Republicans hope it also provides political cover
against charges by some Democrats that the bill would undermine the
federal insurance program for the elderly and disabled. The group will
support the bill with $7 million worth of newspaper and television
advertising this week, and officials said it was prepared to spend more. Still, some Democrats, led by Senator Edward M. Kennedy of Mr. Kennedy stopped short of threatening a filibuster to block the
bill, which is expected to gain support from some moderate and
conservative Democrats. Democrats were expected to discuss the measure in
a caucus on Tuesday. But leading Republican strategists said they did not
expect a filibuster because, they asserted, the political fallout for the
Democrats from blocking a vote would be so great. After Mr. Kennedy's scathing remarks on Monday, Senator Mitch McConnell
of Republican spokesmen expressed confidence that they could sell the plan
to their own ranks, including conservatives long troubled by such a large
expansion of an entitlement program. "We're very upbeat," said
John P. Feehery, spokesman for J. Dennis Hastert of But the vote counts are only beginning, and the text of the legislation
is still unavailable to most lawmakers. The sweeping legislation, estimated to cost $400 billion over 10 years,
offers outpatient drug coverage for the first time to the 40 million
Medicare beneficiaries. But the biggest issue in the coming battle is not the drug benefits. In
the complicated compromise that produced the legislation, Republicans
insisted on many provisions intended to inject market forces and more
competition into Medicare, which they argue will ultimately lead to
better, more cost-effective care. Liberal Democrats say the changes would destabilize the whole program,
increase premiums for people in traditional Medicare and coerce them into
joining private health plans. Under the bill, Mr. Kennedy argued on the
floor on Monday, Congress would provide lavish subsidies to private health
plans, giving them an unfair advantage in competition with the traditional
government-run Medicare program. Another battle looms over a section of the bill that would establish a
new mechanism to hold down Medicare costs, by setting limits on the use of
general tax revenues. Republicans say this would force the president and
Congress to be fiscally responsible. Democrats say it would encourage
Congress to cut Medicare benefits and increase premiums. The drug benefit itself falls short of what many working people
typically receive. Scheduled to begin in 2006, the benefit would cover 75
percent of an individual's drug costs up to $2,200 a year, with premiums
averaging $35 a month and a deductible of $275 a year. Medicare would then
pay nothing until the beneficiary had spent $3,600 out of pocket. Medicare
would pay 95 percent of the cost of each prescription beyond that. In an interview, William D. Novelli, chief executive of AARP, said:
"We strongly support the legislation and will work hard for its
passage. This is not a perfect bill, but Republicans working on the bill have frequently consulted AARP,
formerly known as the American Association of Retired Persons. The
endorsement infuriated some of AARP's usual allies in the Democratic Party
and labor unions. "We are very troubled by the posture of AARP during negotiations
over the Medicare drug legislation," said Alan V. Reuther,
legislative director of the United Automobile Workers. "It appears
AARP has made a decision that it wants to cozy up to the administration.
It's buying into a bill that will make many seniors worse off in terms of
their health coverage." The Democratic leader of the House, Representative Nancy Pelosi of Senator Tom Daschle of Democrats said the group's leaders were out of touch with their
members. In 1988, they noted, the group endorsed a bill expanding Medicare
to cover catastrophic costs, only to see it repealed a year later after an
outcry from the elderly, who said the added benefit was not worth the
extra cost. But AARP executives said they desperately wanted to establish a basic
drug benefit, and Mr. Novelli said his group would ask Congress to expand
it in the future. Under the bill, Mr. Novelli said, "two-thirds of
Medicare beneficiaries will be better off with regard to drug
coverage." The legislation, expected to reach the floor of both chambers before
Thanksgiving, is the product of months of negotiations. The House and the
Senate passed sharply differing versions of the bill last summer. Now the
agreement reached over the weekend moves the legislation closer to
enactment than ever before. For all their optimism, Republican leaders still face divisions in
their ranks. Representative Jeff Flake, Republican of The political stakes for both parties are immense. Republicans are
eager to produce a benefit long promised to a critical voting group. Liberal Democrats with qualms about the legislation face complicated
calculations on both policy and political grounds. Should they vote
against it, and hope that another opportunity to create a better bill
comes around again? Or should they take the chance on what they see as a
flawed measure? "Getting a large benefit for lots of people that didn't exist
before is very alluring," said Senator Charles E. Schumer, Democrat
of New York. Yet Mr. Schumer said he had grave concerns about other parts
of the bill that he called "a total sellout to the pharmaceutical
industry." He concluded, "I think people are in a real
quandary." The question of whether to filibuster is equally fraught. Some Democrats argue that those who oppose the bill should vote against it, but let it become law, convinced that it will prove to be profoundly unpopular with the elderly. Making the case for a change would then become far easier. Moreover, they say, a filibuster would give the Republicans a powerful weapon against Democrats next year, when they could accuse Democrats of obstructionism. Copyright
© 2002 Global Action on Aging |